Immuno-Oncology Biomarkers

As pharmaceutical and biotechnology companies increase their investment in immuno-oncology programs to facilitate rapid development of novel .. Read more immunotherapies, there is increasing pressure to discover and validate relevant biomarkers. Cambridge Healthtech Institute’s Annual Immuno-Oncology Biomarkers meeting will bring together biomarker experts from industry and academia to address rapid development of predictive and prognostic IO biomarkers, utility of these biomarkers in clinical trials, and their potential as companion diagnostics.